Projecting the incidence and costs of major cardiovascular and kidney complications of type 2 diabetes with widespread SGLT2i and GLP-1 RA use: a cost-effectiveness analysis

AIMS/HYPOTHESIS: Whether sodium–glucose co-transporter 2 inhibitors (SGLT2is) or glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are cost-effective based solely on their cardiovascular and kidney benefits is unknown. We projected the health and economic outcomes due to myocardial infarction (M...

Descripción completa

Detalles Bibliográficos
Autores principales: Morton, Jedidiah I., Marquina, Clara, Shaw, Jonathan E., Liew, Danny, Polkinghorne, Kevan R., Ademi, Zanfina, Magliano, Dianna J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9947091/
https://www.ncbi.nlm.nih.gov/pubmed/36404375
http://dx.doi.org/10.1007/s00125-022-05832-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9947091/
https://www.ncbi.nlm.nih.gov/pubmed/36404375
http://dx.doi.org/10.1007/s00125-022-05832-0

Ejemplares similares